{"transactions":[{"id":2111931,"issuer":{"id":3552,"kind":"organization","name":"Protagonist Therapeutics, Inc","symbol":"PTGX"},"owners":[{"id":122295,"kind":"person","name":"Liu David Y","position":1,"cik":"0001675881","reported_name":"Liu David Y","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief R&D Strategy Officer"}}],"security":"Stock Option (right to buy)","published_at":"2022-11-17T23:24:16.000Z","date":"2022-11-16","kind":"exercise","acquired":false,"shares":35331,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The stock option is vested in full."}],"balance_after":0,"derivative":{"exercise_price":4.21,"expiration_date":"2026-04-29","underlying":"Common Stock","underlying_shares":35331},"source":{"system":"sec-edgar","filing":"0001104659-22-119974","document":"tm2230775-3_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":10,"url":"https://www.sec.gov/Archives/edgar/data/1377121/000110465922119974/tm2230775-3_4seq1.xml","form_type":"4"}},{"id":2111930,"issuer":{"id":3552,"kind":"organization","name":"Protagonist Therapeutics, Inc","symbol":"PTGX"},"owners":[{"id":122295,"kind":"person","name":"Liu David Y","position":1,"cik":"0001675881","reported_name":"Liu David Y","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief R&D Strategy Officer"}}],"security":"Stock Option (right to buy)","published_at":"2022-11-17T23:24:16.000Z","date":"2022-11-16","kind":"exercise","acquired":false,"shares":35656,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The stock option is vested in full."}],"balance_after":0,"derivative":{"exercise_price":1.16,"expiration_date":"2025-10-28","underlying":"Common Stock","underlying_shares":35656},"source":{"system":"sec-edgar","filing":"0001104659-22-119974","document":"tm2230775-3_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":9,"url":"https://www.sec.gov/Archives/edgar/data/1377121/000110465922119974/tm2230775-3_4seq1.xml","form_type":"4"}},{"id":2111929,"issuer":{"id":3552,"kind":"organization","name":"Protagonist Therapeutics, Inc","symbol":"PTGX"},"owners":[{"id":122295,"kind":"person","name":"Liu David Y","position":1,"cik":"0001675881","reported_name":"Liu David Y","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief R&D Strategy Officer"}}],"security":"Stock Option (right to buy)","published_at":"2022-11-17T23:24:16.000Z","date":"2022-11-16","kind":"exercise","acquired":false,"shares":5999,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The stock option is vested in full."}],"balance_after":0,"derivative":{"exercise_price":1.89,"expiration_date":"2025-03-26","underlying":"Common Stock","underlying_shares":5999},"source":{"system":"sec-edgar","filing":"0001104659-22-119974","document":"tm2230775-3_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/1377121/000110465922119974/tm2230775-3_4seq1.xml","form_type":"4"}},{"id":2111928,"issuer":{"id":3552,"kind":"organization","name":"Protagonist Therapeutics, Inc","symbol":"PTGX"},"owners":[{"id":122295,"kind":"person","name":"Liu David Y","position":1,"cik":"0001675881","reported_name":"Liu David Y","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief R&D Strategy Officer"}}],"security":"Stock Option (right to buy)","published_at":"2022-11-17T23:24:16.000Z","date":"2022-11-16","kind":"exercise","acquired":false,"shares":9726,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The stock option is vested in full."}],"balance_after":0,"derivative":{"exercise_price":1.89,"expiration_date":"2024-10-22","underlying":"Common Stock","underlying_shares":9726},"source":{"system":"sec-edgar","filing":"0001104659-22-119974","document":"tm2230775-3_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1377121/000110465922119974/tm2230775-3_4seq1.xml","form_type":"4"}},{"id":2111927,"issuer":{"id":3552,"kind":"organization","name":"Protagonist Therapeutics, Inc","symbol":"PTGX"},"owners":[{"id":122295,"kind":"person","name":"Liu David Y","position":1,"cik":"0001675881","reported_name":"Liu David Y","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief R&D Strategy Officer"}}],"security":"Stock Option (right to buy)","published_at":"2022-11-17T23:24:16.000Z","date":"2022-11-16","kind":"exercise","acquired":false,"shares":13767,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The stock option is vested in full."}],"balance_after":0,"derivative":{"exercise_price":0.87,"expiration_date":"2023-09-26","underlying":"Common Stock","underlying_shares":13767},"source":{"system":"sec-edgar","filing":"0001104659-22-119974","document":"tm2230775-3_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1377121/000110465922119974/tm2230775-3_4seq1.xml","form_type":"4"}},{"id":2111926,"issuer":{"id":3552,"kind":"organization","name":"Protagonist Therapeutics, Inc","symbol":"PTGX"},"owners":[{"id":122295,"kind":"person","name":"Liu David Y","position":1,"cik":"0001675881","reported_name":"Liu David Y","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief R&D Strategy Officer"}}],"security":"Common Stock","published_at":"2022-11-17T23:24:16.000Z","date":"2022-11-16","kind":"exercise","acquired":true,"shares":35331,"price":4.21,"value":148743.51,"ownership":{"direct":true},"balance_after":167590,"source":{"system":"sec-edgar","filing":"0001104659-22-119974","document":"tm2230775-3_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1377121/000110465922119974/tm2230775-3_4seq1.xml","form_type":"4"}},{"id":2111925,"issuer":{"id":3552,"kind":"organization","name":"Protagonist Therapeutics, Inc","symbol":"PTGX"},"owners":[{"id":122295,"kind":"person","name":"Liu David Y","position":1,"cik":"0001675881","reported_name":"Liu David Y","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief R&D Strategy Officer"}}],"security":"Common Stock","published_at":"2022-11-17T23:24:16.000Z","date":"2022-11-16","kind":"exercise","acquired":true,"shares":35656,"price":1.16,"value":41360.96,"ownership":{"direct":true},"balance_after":132259,"source":{"system":"sec-edgar","filing":"0001104659-22-119974","document":"tm2230775-3_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1377121/000110465922119974/tm2230775-3_4seq1.xml","form_type":"4"}},{"id":2111924,"issuer":{"id":3552,"kind":"organization","name":"Protagonist Therapeutics, Inc","symbol":"PTGX"},"owners":[{"id":122295,"kind":"person","name":"Liu David Y","position":1,"cik":"0001675881","reported_name":"Liu David Y","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief R&D Strategy Officer"}}],"security":"Common Stock","published_at":"2022-11-17T23:24:16.000Z","date":"2022-11-16","kind":"exercise","acquired":true,"shares":5999,"price":1.89,"value":11338.11,"ownership":{"direct":true},"balance_after":96603,"source":{"system":"sec-edgar","filing":"0001104659-22-119974","document":"tm2230775-3_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1377121/000110465922119974/tm2230775-3_4seq1.xml","form_type":"4"}},{"id":2111923,"issuer":{"id":3552,"kind":"organization","name":"Protagonist Therapeutics, Inc","symbol":"PTGX"},"owners":[{"id":122295,"kind":"person","name":"Liu David Y","position":1,"cik":"0001675881","reported_name":"Liu David Y","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief R&D Strategy Officer"}}],"security":"Common Stock","published_at":"2022-11-17T23:24:16.000Z","date":"2022-11-16","kind":"exercise","acquired":true,"shares":9726,"price":1.89,"value":18382.14,"ownership":{"direct":true},"balance_after":90604,"source":{"system":"sec-edgar","filing":"0001104659-22-119974","document":"tm2230775-3_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1377121/000110465922119974/tm2230775-3_4seq1.xml","form_type":"4"}},{"id":2111922,"issuer":{"id":3552,"kind":"organization","name":"Protagonist Therapeutics, Inc","symbol":"PTGX"},"owners":[{"id":122295,"kind":"person","name":"Liu David Y","position":1,"cik":"0001675881","reported_name":"Liu David Y","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief R&D Strategy Officer"}}],"security":"Common Stock","published_at":"2022-11-17T23:24:16.000Z","date":"2022-11-16","kind":"exercise","acquired":true,"shares":13767,"price":0.87,"value":11977.29,"ownership":{"direct":true},"footnotes":[{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F1","text":"Includes an aggregate of 573 shares acquired by the Reporting Person under the Issuer's 2016 Employee Stock Purchase Plan on March 9, 2022 and September 9, 2022."}],"balance_after":80878,"source":{"system":"sec-edgar","filing":"0001104659-22-119974","document":"tm2230775-3_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1377121/000110465922119974/tm2230775-3_4seq1.xml","form_type":"4"}},{"id":2360163,"issuer":{"id":3552,"kind":"organization","name":"Protagonist Therapeutics, Inc","symbol":"PTGX"},"owners":[{"id":122295,"kind":"person","name":"Liu David Y","position":1,"cik":"0001675881","reported_name":"Liu David Y","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Common Stock","published_at":"2022-03-03T01:38:59.000Z","date":"2022-02-28","kind":"tax_withholding","acquired":false,"shares":2119,"price":24.28,"value":51449.32,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents shares withheld by the Issuer to satisfy tax withholding obligations in connection with the release of 6,125 vested restricted stock units on February 28, 2022."}],"balance_after":66538,"source":{"system":"sec-edgar","filing":"0001104659-22-029519","document":"tm228264-1_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1377121/000110465922029519/tm228264-1_4seq1.xml","form_type":"4"}},{"id":2388126,"issuer":{"id":3552,"kind":"organization","name":"Protagonist Therapeutics, Inc","symbol":"PTGX"},"owners":[{"id":122295,"kind":"person","name":"Liu David Y","position":1,"cik":"0001675881","reported_name":"Liu David Y","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Stock Option (right to buy)","published_at":"2022-02-18T00:25:38.000Z","date":"2022-02-15","kind":"grant","acquired":false,"shares":60000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The stock option vests in 48 equal monthly installments following the date of grant."}],"balance_after":60000,"derivative":{"exercise_price":28.73,"expiration_date":"2032-02-14","underlying":"Common Stock","underlying_shares":60000},"source":{"system":"sec-edgar","filing":"0001104659-22-024840","document":"tm227111-3_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1377121/000110465922024840/tm227111-3_4seq1.xml","form_type":"4"}},{"id":2388125,"issuer":{"id":3552,"kind":"organization","name":"Protagonist Therapeutics, Inc","symbol":"PTGX"},"owners":[{"id":122295,"kind":"person","name":"Liu David Y","position":1,"cik":"0001675881","reported_name":"Liu David Y","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Common Stock","published_at":"2022-02-18T00:25:38.000Z","date":"2022-02-15","kind":"grant","acquired":true,"shares":10000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents grant of restricted stock units payable solely in common stock that will vest in three annual installments on February 15, 2023, 2024 and 2025."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Includes an aggregate of 403 shares acquired by the Reporting Person under the Issuer's 2016 Employee Stock Purchase Plan on September 9, 2021."}],"balance_after":68657,"source":{"system":"sec-edgar","filing":"0001104659-22-024840","document":"tm227111-3_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1377121/000110465922024840/tm227111-3_4seq1.xml","form_type":"4"}},{"id":2596009,"issuer":{"id":3552,"kind":"organization","name":"Protagonist Therapeutics, Inc","symbol":"PTGX"},"owners":[{"id":122295,"kind":"person","name":"Liu David Y","position":1,"cik":"0001675881","reported_name":"Liu David Y","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Stock Option (right to buy)","published_at":"2021-08-19T21:49:39.000Z","date":"2021-08-17","kind":"exercise","acquired":false,"shares":10000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"The stock option is vested in full."}],"balance_after":13767,"derivative":{"exercise_price":0.87,"expiration_date":"2023-09-26","underlying":"Common Stock","underlying_shares":10000},"source":{"system":"sec-edgar","filing":"0001104659-21-107818","document":"tm2125489-1_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1377121/000110465921107818/tm2125489-1_4seq1.xml","form_type":"4"}},{"id":2596008,"issuer":{"id":3552,"kind":"organization","name":"Protagonist Therapeutics, Inc","symbol":"PTGX"},"owners":[{"id":122295,"kind":"person","name":"Liu David Y","position":1,"cik":"0001675881","reported_name":"Liu David Y","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Common Stock","published_at":"2021-08-19T21:49:39.000Z","date":"2021-08-17","kind":"sale","acquired":false,"shares":14779,"price":47.56,"value":702889.24,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F2","text":"The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on July 7, 2021."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $47.10 to $48.34. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F1","text":"Includes an aggregate of 606 shares acquired by the Reporting Person under the Issuer's 2016 Employee Stock Purchase Plan on March 9, 2021."}],"balance_after":58254,"source":{"system":"sec-edgar","filing":"0001104659-21-107818","document":"tm2125489-1_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1377121/000110465921107818/tm2125489-1_4seq1.xml","form_type":"4"}},{"id":2596007,"issuer":{"id":3552,"kind":"organization","name":"Protagonist Therapeutics, Inc","symbol":"PTGX"},"owners":[{"id":122295,"kind":"person","name":"Liu David Y","position":1,"cik":"0001675881","reported_name":"Liu David Y","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Common Stock","published_at":"2021-08-19T21:49:39.000Z","date":"2021-08-17","kind":"exercise","acquired":true,"shares":10000,"price":0.87,"value":8700.0,"ownership":{"direct":true},"footnotes":[{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F1","text":"Includes an aggregate of 606 shares acquired by the Reporting Person under the Issuer's 2016 Employee Stock Purchase Plan on March 9, 2021."}],"balance_after":73033,"source":{"system":"sec-edgar","filing":"0001104659-21-107818","document":"tm2125489-1_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1377121/000110465921107818/tm2125489-1_4seq1.xml","form_type":"4"}},{"id":2829431,"issuer":{"id":3552,"kind":"organization","name":"Protagonist Therapeutics, Inc","symbol":"PTGX"},"owners":[{"id":122295,"kind":"person","name":"Liu David Y","position":1,"cik":"0001675881","reported_name":"Liu David Y","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Stock Option (right to buy)","published_at":"2021-02-26T23:31:28.000Z","date":"2021-02-26","kind":"grant","acquired":true,"shares":65000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The stock option vests in 48 equal monthly installments following the date of grant."}],"balance_after":65000,"derivative":{"exercise_price":23.57,"expiration_date":"2031-02-25","underlying":"Common Stock","underlying_shares":65000},"source":{"system":"sec-edgar","filing":"0001209191-21-014976","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1377121/000120919121014976/doc4.xml","form_type":"4"}},{"id":2829430,"issuer":{"id":3552,"kind":"organization","name":"Protagonist Therapeutics, Inc","symbol":"PTGX"},"owners":[{"id":122295,"kind":"person","name":"Liu David Y","position":1,"cik":"0001675881","reported_name":"Liu David Y","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Common Stock","published_at":"2021-02-26T23:31:28.000Z","date":"2021-02-26","kind":"grant","acquired":true,"shares":10000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents grant of restricted stock units payable solely in common stock that will become fully vested on February 26, 2024."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Includes an aggregate of 2,625 shares acquired by the Reporting Person under the Issuer's 2016 Employee Stock Purchase Plan on September 9, 2019 and March 9, 2020."}],"balance_after":62427,"source":{"system":"sec-edgar","filing":"0001209191-21-014976","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1377121/000120919121014976/doc4.xml","form_type":"4"}},{"id":3241036,"issuer":{"id":3552,"kind":"organization","name":"Protagonist Therapeutics, Inc","symbol":"PTGX"},"owners":[{"id":122295,"kind":"person","name":"Liu David Y","position":1,"cik":"0001675881","reported_name":"Liu David Y","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Stock Option (right to buy)","published_at":"2020-02-28T22:46:46.000Z","date":"2020-02-28","kind":"grant","acquired":true,"shares":70000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The stock option vests in 48 equal monthly installments following the date of grant."}],"balance_after":70000,"derivative":{"exercise_price":7.8,"expiration_date":"2030-02-27","underlying":"Common Stock","underlying_shares":70000},"source":{"system":"sec-edgar","filing":"0001209191-20-014092","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1377121/000120919120014092/doc4.xml","form_type":"4"}},{"id":3443437,"issuer":{"id":3552,"kind":"organization","name":"Protagonist Therapeutics, Inc","symbol":"PTGX"},"owners":[{"id":122295,"kind":"person","name":"Liu David Y","position":1,"cik":"0001675881","reported_name":"Liu David Y","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Common Stock","published_at":"2019-08-08T22:17:23.000Z","date":"2019-08-06","kind":"sale","acquired":false,"shares":3395,"price":8.8495,"value":30044.0525,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported on this Form 4 represent shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of Restricted Stock Units. These sales are mandated by the Issuer's election under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a \"sell to cover\" transaction and do not represent discretionary trades by the Reporting Person."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $8.80 to $9.2255, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F3","text":"Includes 2,000 shares acquired by the Reporting Person under the Issuer's 2016 Employee Stock Purchase Plan on March 8, 2019."}],"balance_after":49802,"source":{"system":"sec-edgar","filing":"0001209191-19-045196","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1377121/000120919119045196/doc4.xml","form_type":"4"}},{"id":3618653,"issuer":{"id":3552,"kind":"organization","name":"Protagonist Therapeutics, Inc","symbol":"PTGX"},"owners":[{"id":122295,"kind":"person","name":"Liu David Y","position":1,"cik":"0001675881","reported_name":"Liu David Y","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Employee Stock Option (right to buy)","published_at":"2019-03-04T23:35:51.000Z","date":"2019-02-28","kind":"grant","acquired":true,"shares":90000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The stock option vests in 48 equal monthly installments following the date of grant."}],"balance_after":90000,"derivative":{"exercise_price":8.02,"expiration_date":"2029-02-27","underlying":"Common Stock","underlying_shares":90000},"source":{"system":"sec-edgar","filing":"0001209191-19-015939","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1377121/000120919119015939/doc4.xml","form_type":"4"}},{"id":3618652,"issuer":{"id":3552,"kind":"organization","name":"Protagonist Therapeutics, Inc","symbol":"PTGX"},"owners":[{"id":122295,"kind":"person","name":"Liu David Y","position":1,"cik":"0001675881","reported_name":"Liu David Y","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Common Stock","published_at":"2019-03-04T23:35:51.000Z","date":"2019-03-01","kind":"sale","acquired":false,"shares":810,"price":8.03,"value":6504.3,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"The sales reported on this Form 4 represent shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of Restricted Stock Units. These sales are mandated by the Issuer's election under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a \"sell to cover\" transaction and do not represent discretionary trades by the Reporting Person."}],"balance_after":51197,"source":{"system":"sec-edgar","filing":"0001209191-19-015939","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1377121/000120919119015939/doc4.xml","form_type":"4"}},{"id":3618651,"issuer":{"id":3552,"kind":"organization","name":"Protagonist Therapeutics, Inc","symbol":"PTGX"},"owners":[{"id":122295,"kind":"person","name":"Liu David Y","position":1,"cik":"0001675881","reported_name":"Liu David Y","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Common Stock","published_at":"2019-03-04T23:35:51.000Z","date":"2019-02-28","kind":"grant","acquired":true,"shares":15000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents grant of the restricted stock units payable solely in common stock that vest in equal annual installments over four years from the grant date."}],"balance_after":52007,"source":{"system":"sec-edgar","filing":"0001209191-19-015939","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1377121/000120919119015939/doc4.xml","form_type":"4"}},{"id":3667913,"issuer":{"id":3552,"kind":"organization","name":"Protagonist Therapeutics, Inc","symbol":"PTGX"},"owners":[{"id":122295,"kind":"person","name":"Liu David Y","position":1,"cik":"0001675881","reported_name":"Liu David Y","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Common Stock","published_at":"2019-02-08T22:30:02.000Z","date":"2019-02-06","kind":"sale","acquired":false,"shares":3821,"price":7.7366,"value":29561.5486,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported on this Form 4 represent shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of Restricted Stock Units. These sales are mandated by the Issuer's election under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a \"sell to cover\" transaction and do not represent discretionary trades by the Reporting Person."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price.  These shares were sold in multiple transactions at prices ranging from $7.71 to $8.1377, inclusive.  The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range."}],"balance_after":37007,"source":{"system":"sec-edgar","filing":"0001209191-19-008679","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1377121/000120919119008679/doc4.xml","form_type":"4"}},{"id":3839829,"issuer":{"id":3552,"kind":"organization","name":"Protagonist Therapeutics, Inc","symbol":"PTGX"},"owners":[{"id":122295,"kind":"person","name":"Liu David Y","position":1,"cik":"0001675881","reported_name":"Liu David Y","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Stock Option (right to buy)","published_at":"2018-08-18T00:22:54.000Z","date":"2018-08-15","kind":"grant","acquired":true,"shares":17200,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"1/3rd of the total number of shares underlying this option shall vest on each of February 5, 2019, August 5, 2019 and February 5, 2020."}],"balance_after":17200,"derivative":{"exercise_price":8.58,"expiration_date":"2028-08-14","underlying":"Common Stock","underlying_shares":17200},"source":{"system":"sec-edgar","filing":"0001209191-18-047543","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1377121/000120919118047543/doc4.xml","form_type":"4"}},{"id":3839828,"issuer":{"id":3552,"kind":"organization","name":"Protagonist Therapeutics, Inc","symbol":"PTGX"},"owners":[{"id":122295,"kind":"person","name":"Liu David Y","position":1,"cik":"0001675881","reported_name":"Liu David Y","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Common Stock","published_at":"2018-08-18T00:22:54.000Z","date":"2018-08-15","kind":"grant","acquired":true,"shares":25800,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents grant of the restricted stock units payable solely in common stock that vest as follows: 1/3rd of the total number of shares shall vest on each of February 5, 2019, August 5, 2019 and February 5, 2020."}],"balance_after":40828,"source":{"system":"sec-edgar","filing":"0001209191-18-047543","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1377121/000120919118047543/doc4.xml","form_type":"4"}},{"id":3997995,"issuer":{"id":3552,"kind":"organization","name":"Protagonist Therapeutics, Inc","symbol":"PTGX"},"owners":[{"id":122295,"kind":"person","name":"Liu David Y","position":1,"cik":"0001675881","reported_name":"Liu David Y","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Employee Stock Option (right to buy)","published_at":"2018-03-13T20:48:52.000Z","date":"2018-03-12","kind":"exercise","acquired":false,"shares":3500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The option vests over a four-year period, with 1/48th of the shares subject to the option vesting on the last day of each month following the vesting commencement date, subject to the Reporting Person continuing to be a service provider of the Issuer through each such date."}],"balance_after":35331,"derivative":{"exercise_price":4.21,"expiration_date":"2026-04-29","underlying":"Common Stock","underlying_shares":3500},"source":{"system":"sec-edgar","filing":"0001209191-18-019253","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1377121/000120919118019253/doc4.xml","form_type":"4"}},{"id":3997994,"issuer":{"id":3552,"kind":"organization","name":"Protagonist Therapeutics, Inc","symbol":"PTGX"},"owners":[{"id":122295,"kind":"person","name":"Liu David Y","position":1,"cik":"0001675881","reported_name":"Liu David Y","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Common Stock","published_at":"2018-03-13T20:48:52.000Z","date":"2018-03-12","kind":"sale","acquired":false,"shares":3500,"price":21.2857,"value":74499.95,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on February 6, 2017."}],"balance_after":15028,"source":{"system":"sec-edgar","filing":"0001209191-18-019253","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1377121/000120919118019253/doc4.xml","form_type":"4"}},{"id":3997993,"issuer":{"id":3552,"kind":"organization","name":"Protagonist Therapeutics, Inc","symbol":"PTGX"},"owners":[{"id":122295,"kind":"person","name":"Liu David Y","position":1,"cik":"0001675881","reported_name":"Liu David Y","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Common Stock","published_at":"2018-03-13T20:48:52.000Z","date":"2018-03-12","kind":"exercise","acquired":true,"shares":3500,"price":4.21,"value":14735.0,"ownership":{"direct":true},"footnotes":[{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F1","text":"Includes 1,706 shares acquired by the Reporting Person under the Issuer's 2016 Employee Stock Purchase Plan on March 9, 2018."}],"balance_after":18528,"source":{"system":"sec-edgar","filing":"0001209191-18-019253","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1377121/000120919118019253/doc4.xml","form_type":"4"}},{"id":4019667,"issuer":{"id":3552,"kind":"organization","name":"Protagonist Therapeutics, Inc","symbol":"PTGX"},"owners":[{"id":122295,"kind":"person","name":"Liu David Y","position":1,"cik":"0001675881","reported_name":"Liu David Y","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Employee Stock Option (right to buy)","published_at":"2018-03-03T00:17:22.000Z","date":"2018-03-02","kind":"exercise","acquired":false,"shares":875,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"The option vests over a four-year period, with 1/4th of the shares subject to the option vesting on the one year anniversary of the vesting commencement date, and 1/36th of the remaining shares subject to the option vesting each month, subject to the Reporting Person continuing to be a service provider of the Issuer through each such date."}],"balance_after":9725,"derivative":{"exercise_price":1.89,"expiration_date":"2024-10-22","underlying":"Common Stock","underlying_shares":875},"source":{"system":"sec-edgar","filing":"0001209191-18-016034","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1377121/000120919118016034/doc4.xml","form_type":"4"}},{"id":4019666,"issuer":{"id":3552,"kind":"organization","name":"Protagonist Therapeutics, Inc","symbol":"PTGX"},"owners":[{"id":122295,"kind":"person","name":"Liu David Y","position":1,"cik":"0001675881","reported_name":"Liu David Y","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Employee Stock Option (right to buy)","published_at":"2018-03-03T00:17:22.000Z","date":"2018-02-28","kind":"grant","acquired":true,"shares":56500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The shares underlying this option shall vest as to 25% after one year following the grant date, and the remainder will vest in equal monthly installments over the following three years."}],"balance_after":56500,"derivative":{"exercise_price":16.95,"expiration_date":"2028-02-27","underlying":"Common Stock","underlying_shares":56500},"source":{"system":"sec-edgar","filing":"0001209191-18-016034","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1377121/000120919118016034/doc4.xml","form_type":"4"}},{"id":4019665,"issuer":{"id":3552,"kind":"organization","name":"Protagonist Therapeutics, Inc","symbol":"PTGX"},"owners":[{"id":122295,"kind":"person","name":"Liu David Y","position":1,"cik":"0001675881","reported_name":"Liu David Y","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Common Stock","published_at":"2018-03-03T00:17:22.000Z","date":"2018-03-02","kind":"sale","acquired":false,"shares":875,"price":20,"value":17500.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on February 6, 2017."}],"balance_after":13322,"source":{"system":"sec-edgar","filing":"0001209191-18-016034","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1377121/000120919118016034/doc4.xml","form_type":"4"}},{"id":4019664,"issuer":{"id":3552,"kind":"organization","name":"Protagonist Therapeutics, Inc","symbol":"PTGX"},"owners":[{"id":122295,"kind":"person","name":"Liu David Y","position":1,"cik":"0001675881","reported_name":"Liu David Y","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Common Stock","published_at":"2018-03-03T00:17:22.000Z","date":"2018-03-02","kind":"exercise","acquired":true,"shares":875,"price":1.89,"value":1653.75,"ownership":{"direct":true},"balance_after":14197,"source":{"system":"sec-edgar","filing":"0001209191-18-016034","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1377121/000120919118016034/doc4.xml","form_type":"4"}},{"id":4019663,"issuer":{"id":3552,"kind":"organization","name":"Protagonist Therapeutics, Inc","symbol":"PTGX"},"owners":[{"id":122295,"kind":"person","name":"Liu David Y","position":1,"cik":"0001675881","reported_name":"Liu David Y","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Common Stock","published_at":"2018-03-03T00:17:22.000Z","date":"2018-02-28","kind":"grant","acquired":true,"shares":9500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents grant of the restricted stock units payable solely in common stock that vest in equal annual installments over four years from the grant date."}],"balance_after":13322,"source":{"system":"sec-edgar","filing":"0001209191-18-016034","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1377121/000120919118016034/doc4.xml","form_type":"4"}},{"id":4097721,"issuer":{"id":3552,"kind":"organization","name":"Protagonist Therapeutics, Inc","symbol":"PTGX"},"owners":[{"id":122295,"kind":"person","name":"Liu David Y","position":1,"cik":"0001675881","reported_name":"Liu David Y","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Employee Stock Option (right to buy)","published_at":"2018-01-17T21:34:26.000Z","date":"2018-01-16","kind":"exercise","acquired":false,"shares":875,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The option vests over a four-year period, with 1/4th of the shares subject to the option vesting on the one year anniversary of the vesting commencement date, and 1/36th of the remaining shares subject to the option vesting each month, subject to the Reporting Person continuing to be a service provider of the Issuer through each such date."}],"balance_after":10600,"derivative":{"exercise_price":1.89,"expiration_date":"2024-10-22","underlying":"Common Stock","underlying_shares":875},"source":{"system":"sec-edgar","filing":"0001209191-18-003954","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1377121/000120919118003954/doc4.xml","form_type":"4"}},{"id":4097720,"issuer":{"id":3552,"kind":"organization","name":"Protagonist Therapeutics, Inc","symbol":"PTGX"},"owners":[{"id":122295,"kind":"person","name":"Liu David Y","position":1,"cik":"0001675881","reported_name":"Liu David Y","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Common Stock","published_at":"2018-01-17T21:34:26.000Z","date":"2018-01-16","kind":"sale","acquired":false,"shares":875,"price":20,"value":17500.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on February 6, 2017."}],"balance_after":3822,"source":{"system":"sec-edgar","filing":"0001209191-18-003954","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1377121/000120919118003954/doc4.xml","form_type":"4"}},{"id":4097719,"issuer":{"id":3552,"kind":"organization","name":"Protagonist Therapeutics, Inc","symbol":"PTGX"},"owners":[{"id":122295,"kind":"person","name":"Liu David Y","position":1,"cik":"0001675881","reported_name":"Liu David Y","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Common Stock","published_at":"2018-01-17T21:34:26.000Z","date":"2018-01-16","kind":"exercise","acquired":true,"shares":875,"price":1.89,"value":1653.75,"ownership":{"direct":true},"balance_after":4697,"source":{"system":"sec-edgar","filing":"0001209191-18-003954","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1377121/000120919118003954/doc4.xml","form_type":"4"}},{"id":4124906,"issuer":{"id":3552,"kind":"organization","name":"Protagonist Therapeutics, Inc","symbol":"PTGX"},"owners":[{"id":122295,"kind":"person","name":"Liu David Y","position":1,"cik":"0001675881","reported_name":"Liu David Y","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Employee Stock Option (right to buy)","published_at":"2017-12-21T02:13:25.000Z","date":"2017-12-18","kind":"exercise","acquired":false,"shares":875,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The option vests over a four-year period, with 1/4th of the shares subject to the option vesting on the one year anniversary of the vesting commencement date, and 1/36th of the remaining shares subject to the option vesting each month, subject to the Reporting Person continuing to be a service provider of the Issuer through each such date."}],"balance_after":11475,"derivative":{"exercise_price":1.89,"expiration_date":"2024-10-22","underlying":"Common Stock","underlying_shares":875},"source":{"system":"sec-edgar","filing":"0001209191-17-066698","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1377121/000120919117066698/doc4.xml","form_type":"4"}},{"id":4124905,"issuer":{"id":3552,"kind":"organization","name":"Protagonist Therapeutics, Inc","symbol":"PTGX"},"owners":[{"id":122295,"kind":"person","name":"Liu David Y","position":1,"cik":"0001675881","reported_name":"Liu David Y","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Common Stock","published_at":"2017-12-21T02:13:25.000Z","date":"2017-12-18","kind":"sale","acquired":false,"shares":875,"price":20,"value":17500.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on February 6, 2017."}],"balance_after":3822,"source":{"system":"sec-edgar","filing":"0001209191-17-066698","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1377121/000120919117066698/doc4.xml","form_type":"4"}},{"id":4124904,"issuer":{"id":3552,"kind":"organization","name":"Protagonist Therapeutics, Inc","symbol":"PTGX"},"owners":[{"id":122295,"kind":"person","name":"Liu David Y","position":1,"cik":"0001675881","reported_name":"Liu David Y","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Common Stock","published_at":"2017-12-21T02:13:25.000Z","date":"2017-12-18","kind":"exercise","acquired":true,"shares":875,"price":1.89,"value":1653.75,"ownership":{"direct":true},"balance_after":4697,"source":{"system":"sec-edgar","filing":"0001209191-17-066698","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1377121/000120919117066698/doc4.xml","form_type":"4"}},{"id":4145995,"issuer":{"id":3552,"kind":"organization","name":"Protagonist Therapeutics, Inc","symbol":"PTGX"},"owners":[{"id":122295,"kind":"person","name":"Liu David Y","position":1,"cik":"0001675881","reported_name":"Liu David Y","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Employee Stock Option (right to buy)","published_at":"2017-12-01T23:56:43.000Z","date":"2017-11-30","kind":"exercise","acquired":false,"shares":875,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The option vests over a four-year period, with 1/4th of the shares subject to the option vesting on the one year anniversary of the vesting commencement date, and 1/36th of the remaining shares subject to the option vesting each month, subject to the Reporting Person continuing to be a service provider of the Issuer through each such date."}],"balance_after":12350,"derivative":{"exercise_price":1.89,"expiration_date":"2024-10-22","underlying":"Common Stock","underlying_shares":875},"source":{"system":"sec-edgar","filing":"0001209191-17-063316","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1377121/000120919117063316/doc4.xml","form_type":"4"}},{"id":4145994,"issuer":{"id":3552,"kind":"organization","name":"Protagonist Therapeutics, Inc","symbol":"PTGX"},"owners":[{"id":122295,"kind":"person","name":"Liu David Y","position":1,"cik":"0001675881","reported_name":"Liu David Y","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Common Stock","published_at":"2017-12-01T23:56:43.000Z","date":"2017-11-30","kind":"sale","acquired":false,"shares":875,"price":20,"value":17500.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on February 6, 2017."}],"balance_after":3822,"source":{"system":"sec-edgar","filing":"0001209191-17-063316","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1377121/000120919117063316/doc4.xml","form_type":"4"}},{"id":4145993,"issuer":{"id":3552,"kind":"organization","name":"Protagonist Therapeutics, Inc","symbol":"PTGX"},"owners":[{"id":122295,"kind":"person","name":"Liu David Y","position":1,"cik":"0001675881","reported_name":"Liu David Y","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Common Stock","published_at":"2017-12-01T23:56:43.000Z","date":"2017-11-30","kind":"grant","acquired":true,"shares":875,"price":1.89,"value":1653.75,"ownership":{"direct":true},"balance_after":4697,"source":{"system":"sec-edgar","filing":"0001209191-17-063316","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1377121/000120919117063316/doc4.xml","form_type":"4"}},{"id":4162058,"issuer":{"id":3552,"kind":"organization","name":"Protagonist Therapeutics, Inc","symbol":"PTGX"},"owners":[{"id":122295,"kind":"person","name":"Liu David Y","position":1,"cik":"0001675881","reported_name":"Liu David Y","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Employee Stock Option (right to buy)","published_at":"2017-11-16T00:14:45.000Z","date":"2017-11-13","kind":"exercise","acquired":false,"shares":3500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"The option vests over a four-year period, with 1/4th of the shares subject to the option vesting on the one year anniversary of the vesting commencement date, and 1/36th of the remaining shares subject to the option vesting each month, subject to the Reporting Person continuing to be a service provider of the Issuer through each such date."}],"balance_after":13225,"derivative":{"exercise_price":1.89,"expiration_date":"2024-10-22","underlying":"Common Stock","underlying_shares":3500},"source":{"system":"sec-edgar","filing":"0001209191-17-061002","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1377121/000120919117061002/doc4.xml","form_type":"4"}},{"id":4162057,"issuer":{"id":3552,"kind":"organization","name":"Protagonist Therapeutics, Inc","symbol":"PTGX"},"owners":[{"id":122295,"kind":"person","name":"Liu David Y","position":1,"cik":"0001675881","reported_name":"Liu David Y","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Employee Stock Option (right to buy)","published_at":"2017-11-16T00:14:45.000Z","date":"2017-11-13","kind":"exercise","acquired":false,"shares":3500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The option vests over a four-year period, with 1/48th of the shares subject to the option vesting on the last day of each month following the vesting commencement date, subject to the Reporting Person continuing to be a service provider of the Issuer through each such date."}],"balance_after":38831,"derivative":{"exercise_price":4.21,"expiration_date":"2026-04-29","underlying":"Common Stock","underlying_shares":3500},"source":{"system":"sec-edgar","filing":"0001209191-17-061002","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1377121/000120919117061002/doc4.xml","form_type":"4"}},{"id":4162056,"issuer":{"id":3552,"kind":"organization","name":"Protagonist Therapeutics, Inc","symbol":"PTGX"},"owners":[{"id":122295,"kind":"person","name":"Liu David Y","position":1,"cik":"0001675881","reported_name":"Liu David Y","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Common Stock","published_at":"2017-11-16T00:14:45.000Z","date":"2017-11-13","kind":"sale","acquired":false,"shares":3500,"price":16.9659,"value":59380.65,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on February 6, 2017."}],"balance_after":3822,"source":{"system":"sec-edgar","filing":"0001209191-17-061002","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1377121/000120919117061002/doc4.xml","form_type":"4"}},{"id":4162055,"issuer":{"id":3552,"kind":"organization","name":"Protagonist Therapeutics, Inc","symbol":"PTGX"},"owners":[{"id":122295,"kind":"person","name":"Liu David Y","position":1,"cik":"0001675881","reported_name":"Liu David Y","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Common Stock","published_at":"2017-11-16T00:14:45.000Z","date":"2017-11-13","kind":"exercise","acquired":true,"shares":3500,"price":1.89,"value":6615.0,"ownership":{"direct":true},"balance_after":7322,"source":{"system":"sec-edgar","filing":"0001209191-17-061002","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1377121/000120919117061002/doc4.xml","form_type":"4"}},{"id":4162054,"issuer":{"id":3552,"kind":"organization","name":"Protagonist Therapeutics, Inc","symbol":"PTGX"},"owners":[{"id":122295,"kind":"person","name":"Liu David Y","position":1,"cik":"0001675881","reported_name":"Liu David Y","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Common Stock","published_at":"2017-11-16T00:14:45.000Z","date":"2017-11-13","kind":"sale","acquired":false,"shares":3500,"price":16.9659,"value":59380.65,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on February 6, 2017."}],"balance_after":3822,"source":{"system":"sec-edgar","filing":"0001209191-17-061002","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1377121/000120919117061002/doc4.xml","form_type":"4"}},{"id":4162053,"issuer":{"id":3552,"kind":"organization","name":"Protagonist Therapeutics, Inc","symbol":"PTGX"},"owners":[{"id":122295,"kind":"person","name":"Liu David Y","position":1,"cik":"0001675881","reported_name":"Liu David Y","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Common Stock","published_at":"2017-11-16T00:14:45.000Z","date":"2017-11-13","kind":"exercise","acquired":true,"shares":3500,"price":4.21,"value":14735.0,"ownership":{"direct":true},"footnotes":[{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F1","text":"Includes 1,822 shares acquired by the Reporting Person under the Issuer's 2016 Employee Stock Purchase Plan on September 8, 2017."}],"balance_after":7322,"source":{"system":"sec-edgar","filing":"0001209191-17-061002","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1377121/000120919117061002/doc4.xml","form_type":"4"}},{"id":4222444,"issuer":{"id":3552,"kind":"organization","name":"Protagonist Therapeutics, Inc","symbol":"PTGX"},"owners":[{"id":122295,"kind":"person","name":"Liu David Y","position":1,"cik":"0001675881","reported_name":"Liu David Y","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Employee Stock Option (right to buy)","published_at":"2017-08-29T23:48:07.000Z","date":"2017-08-28","kind":"exercise","acquired":false,"shares":3500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The option vests over a four-year period, with 1/48th of the shares subject to the option vesting on the last day of each month following the vesting commencement date, subject to the Reporting Person continuing to be a service provider of the Issuer through each such date."}],"balance_after":42331,"derivative":{"exercise_price":4.21,"expiration_date":"2026-04-29","underlying":"Common Stock","underlying_shares":3500},"source":{"system":"sec-edgar","filing":"0001209191-17-050652","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1377121/000120919117050652/doc4.xml","form_type":"4"}},{"id":4222443,"issuer":{"id":3552,"kind":"organization","name":"Protagonist Therapeutics, Inc","symbol":"PTGX"},"owners":[{"id":122295,"kind":"person","name":"Liu David Y","position":1,"cik":"0001675881","reported_name":"Liu David Y","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Common Stock","published_at":"2017-08-29T23:48:07.000Z","date":"2017-08-28","kind":"sale","acquired":false,"shares":3500,"price":15,"value":52500.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on February 6, 2017."}],"balance_after":2000,"source":{"system":"sec-edgar","filing":"0001209191-17-050652","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1377121/000120919117050652/doc4.xml","form_type":"4"}},{"id":4222442,"issuer":{"id":3552,"kind":"organization","name":"Protagonist Therapeutics, Inc","symbol":"PTGX"},"owners":[{"id":122295,"kind":"person","name":"Liu David Y","position":1,"cik":"0001675881","reported_name":"Liu David Y","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Common Stock","published_at":"2017-08-29T23:48:07.000Z","date":"2017-08-28","kind":"exercise","acquired":true,"shares":3500,"price":4.21,"value":14735.0,"ownership":{"direct":true},"balance_after":5500,"source":{"system":"sec-edgar","filing":"0001209191-17-050652","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1377121/000120919117050652/doc4.xml","form_type":"4"}},{"id":4258364,"issuer":{"id":3552,"kind":"organization","name":"Protagonist Therapeutics, Inc","symbol":"PTGX"},"owners":[{"id":122295,"kind":"person","name":"Liu David Y","position":1,"cik":"0001675881","reported_name":"Liu David Y","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Employee Stock Option (right to buy)","published_at":"2017-07-12T21:55:56.000Z","date":"2017-07-10","kind":"exercise","acquired":false,"shares":3500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"The option vests over a four-year period, with 1/4th of the shares subject to the option vesting on the one year anniversary of the vesting commencement date, and 1/36th of the remaining shares subject to the option vesting each month, subject to the Reporting Person continuing to be a service provider of the Issuer through each such date."}],"balance_after":16725,"derivative":{"exercise_price":1.89,"expiration_date":"2024-10-22","underlying":"Common Stock","underlying_shares":3500},"source":{"system":"sec-edgar","filing":"0001209191-17-044940","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1377121/000120919117044940/doc4.xml","form_type":"4"}},{"id":4258363,"issuer":{"id":3552,"kind":"organization","name":"Protagonist Therapeutics, Inc","symbol":"PTGX"},"owners":[{"id":122295,"kind":"person","name":"Liu David Y","position":1,"cik":"0001675881","reported_name":"Liu David Y","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Common Stock","published_at":"2017-07-12T21:55:56.000Z","date":"2017-07-10","kind":"sale","acquired":false,"shares":3500,"price":12.68,"value":44380.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on February 6, 2017."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $12.36 to $12.84. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range."}],"balance_after":2000,"source":{"system":"sec-edgar","filing":"0001209191-17-044940","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1377121/000120919117044940/doc4.xml","form_type":"4"}},{"id":4258362,"issuer":{"id":3552,"kind":"organization","name":"Protagonist Therapeutics, Inc","symbol":"PTGX"},"owners":[{"id":122295,"kind":"person","name":"Liu David Y","position":1,"cik":"0001675881","reported_name":"Liu David Y","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Common Stock","published_at":"2017-07-12T21:55:56.000Z","date":"2017-07-10","kind":"exercise","acquired":true,"shares":3500,"price":1.89,"value":6615.0,"ownership":{"direct":true},"footnotes":[{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F1","text":"Includes 2,000 shares acquired by the Reporting Person under the Issuer's 2016 Employee Stock Purchase Plan on March 9, 2017."}],"balance_after":5500,"source":{"system":"sec-edgar","filing":"0001209191-17-044940","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1377121/000120919117044940/doc4.xml","form_type":"4"}},{"id":4580385,"issuer":{"id":3552,"kind":"organization","name":"Protagonist Therapeutics, Inc","symbol":"PTGX"},"owners":[{"id":122295,"kind":"person","name":"Liu David Y","position":1,"cik":"0001675881","reported_name":"Liu David Y","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Stock Option (right to buy)","published_at":"2016-10-13T20:25:45.000Z","date":"2016-10-11","kind":"grant","acquired":true,"shares":65000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares subject to the option shall vest in 48 equal monthly installments from the vesting commencement date of August 10, 2016."}],"balance_after":65000,"derivative":{"exercise_price":21.58,"expiration_date":"2026-10-11","underlying":"Common Stock","underlying_shares":65000},"source":{"system":"sec-edgar","filing":"0001209191-16-145800","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1377121/000120919116145800/doc4.xml","form_type":"4"}}]}